SEOM Clinical Guideline for bone metastases from solid tumours (2016)

• C. Grávalos ^[1] ; C. Rodríguez ^[2] ; A. Sabino ^[9] ; M. Á. Seguí ^[3] ; J. A. Virizuela ^[4] ; A. Carmona ^[10] ; J. Cassinello ^[5] ; D. Isla ^[6] ; C. Jara ^[7] ; M. Martín ^[8]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  3. [3] Corporació Sanitària Parc Taulí

     Corporació Sanitària Parc Taulí

     Barcelona, España

     
  4. [4] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  5. [5] Hospital Universitario de Guadalajara

     Hospital Universitario de Guadalajara

     Guadalajara, España

     
  6. [6] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  7. [7] Fundación Hospital Alcorcón

     Fundación Hospital Alcorcón

     Alcorcón, España

     
  8. [8] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  9. [9] Grupo ONCOAVANZE, España
  10. [10] Hospital Universitario J.M. Morales Meseguer, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1243-1253
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease. Bone-targeted therapies include zoledronic acid, a potent biphosfonate, and denosumab, an anti-RANKL monoclonal antibody. Both reduce the risk and/or delay the development of SREs in several types of tumours. Radium 233, an alpha-particle emitter, increases overall survival in patients with bone metastases from resistant castration prostate cancer. Multidisciplinary approach is essential and bone surgery and radiotherapy should be integrated in the treatment of bone metastases when necessary. This SEOM Guideline reviews bone metastases pathogenesis, clinical presentations, lab tests, imaging techniques for diagnosis and response assessment, bone-targeted agents, and local therapies, as radiation and surgery, and establishes recommendations for the management of patients with metastases to bone.